HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Wanling Hsu Selected Research

Monoclonal Antibodies

2/2022Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Wanling Hsu Research Topics

Disease

1Hemophilia A (Haemophilia)
02/2022
1Hemorrhage
02/2022
1Respiratory Tract Infections (Respiratory Tract Infection)
02/2022
1Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
01/2018
1Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2018
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2018
1B-Cell Lymphoma (Lymphoma, B Cell)
01/2018

Drug/Important Bio-Agent (IBA)

1emicizumabIBA
02/2022
1Monoclonal AntibodiesIBA
02/2022
1Factor VIII (Coagulation Factor VIII)IBA
02/2022
1obinutuzumabIBA
01/2018